R&D Sponsored Obesity and the endoscopy space: Innovative, minimally invas... According to the World Health Organization (WHO), in 2022, 2.5 billion adults aged 18 years and older were overweight, including over 890 million adults who were living with
News Trump blocks plan for Medicare to cover weight-loss drugs A proposal by the Biden administration to cover weight-loss medicines for obesity under Medicare has been axed by the White House.
News Novo Nordisk looks east for another obesity therapy Novo Nordisk has moved to shore up its obesity pipeline with a $2bn licensing deal for a triple agonist developed by China's United Biotechnology.
News Roche builds in obesity with $5.3bn Zealand licensing deal Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma.
News Novo Nordisk's CagriSema data disappoints investors again Novo Nordisk's obesity candidate CagriSema has underwhelmed in a second phase 3 trial, sending the company's share into a sharp decline.
News Novo Nordisk follows Lilly into DTC obesity drug market Novo Nordisk has launched direct-to-consumer sales of its obesity drug Wegovy for uninsured or under-insured people at $499 per month.